3/15/2007

Medicare officials plan to review the use of three anemia drugs in light of concerns about potentially harmful side effects. The review could determine whether Medicare continues to pay for Amgen's Aranesp and Epogen and Johnson & Johnson's Procrit.

Full Story:
NYTimes.com

Related Summaries